Anthropology
Taurodontism is still a condition of anthropological importance as it was seen in Neanderthals.The trait "is common among extant New World monkeys, apes, and fossil hominins". Related conditions
Although taurodontism is frequently an isolated anomaly, it may be found in association with several other conditions such as: amelogenesis imperfecta, Down syndrome, Klinefelter syndrome, Mohr syndrome, Wolf-Hirschhorn syndrome, Lowe syndrome, ectodermal dysplasia and tricho-dento-osseous syndrome.Taurodontism may be related to:
A retrograde character
A primitive pattern
An autosomal dominant trait
Atavistic feature
An X-linked trait
A mutation

References


== External links ==
Based on experiences with other drugs acting on the renin–angiotensin system, it is theorized that azilsartan could increase the toxicity of lithium and of other drugs increasing potassium levels, such as potassium sparing diuretics. Pharmacology
Mechanism of action
Azilsartan medoxomil lowers blood pressure by blocking the action of angiotensin II at the AT1 receptor, a hormone that contracts blood vessels and reduces water excretion through the kidneys. Pharmacokinetics
Azilsartan medoxomil is quickly absorbed from the gut, independently of food intake. Maximal blood plasma concentrations are reached after one to three hours. The liver enzyme CYP2C9 is involved in the formation of the two main metabolites, which are pharmacologically inactive; they are the O-deethylation and decarboxylation products of azilsartan. Elimination half life is about 11 hours. 55% are excreted via the feces, and 42% via the urine, of which 15% are present as azilsartan and the rest in form of the metabolites. Chemistry
The drug formulation contains the potassium salt of azilsartan medoxomil (codenamed TAK-491), an ester of azilsartans carboxyl group with the alcohol (5-methyl-2-oxo-1,3-dioxol-4-yl)methanol. This ester is more lipophilic than azilsartan itself. History
In February 2011, the U.S. Food and Drug Administration (FDA) approved azilsartan medoxomil for the treatment of high blood pressure in adults. In July 2011, azilsartan medoxomil was approved in the European Union for the treatment of essential hypertension. In March 2012, Health Canada approved the drug for mild to moderate essential hypertension.In December 2014, Valeant Canada acquired the marketing rights to Edarbi and Edarbyclor from Takeda Pharmaceutical. References
External links
"Azilsartan". Drug Information Portal. U.S. National Library of Medicine.